Comparison
3 Phosphoglycerate Dehydrogenase Deficiency C0580190 vs 1p21 3 Microdeletion Syndrome
Clinical comparison between 3 Phosphoglycerate Dehydrogenase Deficiency and 1p21 3 Microdeletion Syndrome for differential diagnosis and treatment planning.
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
A rare metabolic disorder impairing the body's ability to produce serine, an essential amino acid. It primarily affects the nervous system, causing developmental delay, seizures, and movement difficulties. Management includes serine supplementation and anticonvulsants as needed.
1p21 3 Microdeletion Syndrome
6 comparison axes
Onset
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
0-5
1p21 3 Microdeletion Syndrome
0-null
Onset patterns differ
Severity
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
severe
1p21 3 Microdeletion Syndrome
moderate
Different severity levels
Chronic
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
Chronic
1p21 3 Microdeletion Syndrome
Chronic
Differing course
Communicable
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
No
1p21 3 Microdeletion Syndrome
No
Different transmission
Body System
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
metabolic
1p21 3 Microdeletion Syndrome
congenital
Same/different system
Category
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
metabolic
1p21 3 Microdeletion Syndrome
genetic
Different category
Bottom line
3-phosphoglycerate-dehydrogenase-deficiency-C0580190 and 1p21-3-microdeletion-syndrome-C4304578 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 | 1p21 3 Microdeletion Syndrome | Discriminating power |
|---|---|---|---|
| Neurodevelopment | Early severe developmental impairment is typical. | Delay may occur, but the phenotype is not well established. | Moderate |
| Seizures | Early, often difficult seizures are characteristic. | Seizures are not an established defining feature. | High |
| Cause | Disorder of serine biosynthesis, commonly PHGDH-related. | Chromosomal copy loss; effects depend on breakpoints and genes. | High |
When to favor each condition
Choose 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 when
Infant with microcephaly, delay, and early seizures
This pattern better suggests a serine-synthesis disorder.
Moderate
Low plasma or CSF serine
Supports metabolic evaluation but does not alone confirm disease.
High
Biallelic PHGDH variants
Genetic confirmation favors the metabolic diagnosis.
High
Choose 1p21 3 Microdeletion Syndrome when
Microarray detects a 1p21.3 deletion
The finding supports a copy-number abnormality needing genetics review.
High
Delay without serine-pathway abnormality
A chromosomal cause is more plausible, but not proven.
Moderate
The same deletion is found in a relative
Inheritance and clinical meaning require individualized interpretation.
Moderate
How key tests differ
| Test | 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 | 1p21 3 Microdeletion Syndrome | Interpretation |
|---|---|---|---|
| Plasma or CSF amino acids | Low serine, sometimes low glycine, may be found. | No specific amino-acid pattern is established. | An abnormal result prompts confirmation, not a standalone diagnosis. |
| PHGDH testing | Biallelic pathogenic variants are expected. | Not the primary diagnostic test. | Distinguishes a monogenic metabolic disorder. |
| Chromosomal microarray | Usually normal unless another finding coexists. | Detects 1p21.3 copy loss; size and genes matter. | Deletion significance depends on content and clinical correlation. |
Prognosis comparison
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
- Outcome
- Often severe chronic neurodevelopmental disease, with individual variation.
- Factors
- Seizure control, recognition timing, treatment response, and comorbidities.
1p21 3 Microdeletion Syndrome
- Outcome
- Outcome is not established from the sparse supplied data.
- Factors
- Deletion size, involved genes, congenital findings, and support.
Time frame: Lifelong when confirmed; early childhood evaluation is important.
Diagnostic certainty, associated problems, and access to supportive care.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic disability | Severe developmental and movement difficulties are described. Disability is possible, but range and frequency are uncertain. Do not assume equivalent severity. |
| Epilepsy | Seizures may be persistent or difficult to control. Seizure risk is not established from supplied data. Management should follow confirmed clinical findings. |
| Care planning | May require long-term metabolic and seizure care. No standard syndrome-specific therapy is established here. Counseling differs for recessive disease and copy-number variants. |
Patient education highlights
- HighDifferent causes
One is a serine-metabolism disorder; the other is a chromosomal deletion.
- HighConfirmation
Review biochemistry, genes, deletion size, and clinical findings before decisions.
- MediumFamily counseling
Inheritance advice must be individualized by a genetics clinician.